- Home
- CGTX vs FBRX Comparison
CGTX vs FBRX Comparison
Compare CGTX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- FBRX
- Stock Information
- Founded
- CGTX 2007
- FBRX N/A
- Country
- CGTX United States
- FBRX United States
- Employees
- CGTX N/A
- FBRX N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- FBRX Health Care
- Exchange
- CGTX Nasdaq
- FBRX Nasdaq
- Market Cap
- CGTX 158.8M
- FBRX 154.5M
- IPO Year
- CGTX 2021
- FBRX N/A
- Fundamental
- Price
- CGTX $1.74
- FBRX $12.08
- Analyst Decision
- CGTX Strong Buy
- FBRX Strong Buy
- Analyst Count
- CGTX 3
- FBRX 3
- Target Price
- CGTX $2.83
- FBRX $68.00
- AVG Volume (30 Days)
- CGTX 2.1M
- FBRX 92.6K
- Earning Date
- CGTX 11-12-2025
- FBRX 11-13-2025
- Dividend Yield
- CGTX N/A
- FBRX N/A
- EPS Growth
- CGTX N/A
- FBRX N/A
- EPS
- CGTX N/A
- FBRX N/A
- Revenue
- CGTX N/A
- FBRX N/A
- Revenue This Year
- CGTX N/A
- FBRX N/A
- Revenue Next Year
- CGTX N/A
- FBRX N/A
- P/E Ratio
- CGTX N/A
- FBRX N/A
- Revenue Growth
- CGTX N/A
- FBRX N/A
- 52 Week Low
- CGTX $0.22
- FBRX $4.11
- 52 Week High
- CGTX $3.83
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- CGTX 51.92
- FBRX 41.69
- Support Level
- CGTX $1.67
- FBRX $13.76
- Resistance Level
- CGTX $2.00
- FBRX $14.99
- Average True Range (ATR)
- CGTX 0.16
- FBRX 1.22
- MACD
- CGTX 0.02
- FBRX -0.41
- Stochastic Oscillator
- CGTX 59.48
- FBRX 12.75
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).